Caribou Biosciences Files 8-K Report
Ticker: CRBU · Form: 8-K · Filed: Aug 12, 2024 · CIK: 1619856
| Field | Detail |
|---|---|
| Company | Caribou Biosciences, INC. (CRBU) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure
Related Tickers: CRBU
TL;DR
CRBU filed an 8-K, likely containing updates. Watch for details.
AI Summary
On August 12, 2024, Caribou Biosciences, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, along with financial statements and exhibits. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates that Caribou Biosciences is providing updates or disclosures to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a change in risk.
Key Players & Entities
- Caribou Biosciences, Inc. (company) — Registrant
- August 12, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Caribou Biosciences?
The filing is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, as of August 12, 2024.
What is Caribou Biosciences' exact name as specified in its charter?
Caribou Biosciences, Inc.
In which state was Caribou Biosciences incorporated?
Delaware.
What is the principal executive office address for Caribou Biosciences?
2929 7th Street, Suite 105, Berkeley, California 94710.
What is the SIC code for Caribou Biosciences?
2836 - BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 568 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-08-12 08:03:02
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CRBU NASDAQ Global
Filing Documents
- crbu-20240812.htm (8-K) — 27KB
- crbu-20240812xexx991.htm (EX-99.1) — 14KB
- img25401123_0.jpg (GRAPHIC) — 51KB
- tinaalbertson.jpg (GRAPHIC) — 23KB
- 0001619856-24-000068.txt ( ) — 276KB
- crbu-20240812.xsd (EX-101.SCH) — 2KB
- crbu-20240812_lab.xml (EX-101.LAB) — 23KB
- crbu-20240812_pre.xml (EX-101.PRE) — 13KB
- crbu-20240812_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 12, 2024, Caribou Biosciences, Inc. (the "Company") issued a press release announcing the appointment of Tina Albertson as Chief Medical Officer of the Company. A copy of the press release is furnished herewith as Exhibit 99.1 and also is incorporated by reference into this Item 7.01. The information set forth under this Item 7.01, including the accompanying Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, or incorporated by reference in any filing or other document under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing or other document, except as expressly set forth by specific reference in any such filing or other document.
01 Other Events
Item 8.01 Other Events. On August 12, 2024, the Company issued a press release announcing the appointment of Tina Albertson as Chief Medical Officer of the Company.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release Issued by Caribou Biosciences, Inc. on August 12 , 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Caribou Biosciences, Inc. Date: August 12, 2024 By: /s/ Rachel E. Haurwitz Rachel E. Haurwitz President and Chief Executive Officer